×
About 447,124 results
Metronomic capecitabine maintenance extends DFS in triple-negative breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{3c339a48-87d5-48c1-ad53-432291e3e553}/metronomic-capecitabine-maintenance-extends-dfs-in-triple-negative-breast-cancer

May 29th, 2020 - A year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer, according to study results presented at ASCO20 Virtual Scientific Program.

BCMA-targeted CAR-T shows ‘outstanding responses’ in advanced multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/{bc81f18d-afd1-42ae-89ae-185ee74b50be}/bcma-targeted-car-t-shows-outstanding-responses-in-advanced-multiple-myeloma

May 30th, 2020 - Idecabtagene vicleucel induced responses in nearly three-quarters of patients with relapsed or refractory multiple myeloma, according to initial results of the phase 2 KarMMa trial presented during the ASCO20 Virtual Scientific Program.

First-line doxorubicin plus trabectedin effective, safe for metastatic leiomyosarcoma
https://www.healio.com/hematology-oncology/sarcoma/news/online/{28102d3c-c28b-4f98-950f-daa7db22f27d}/first-line-doxorubicin-plus-trabectedin-effective-safe-for-metastatic-leiomyosarcoma

May 30th, 2020 - Doxorubicin in combination with trabectedin appeared to be an effective and safe first-line therapy for metastatic leiomyosarcoma, according to results of the phase 2 LMS-02 study presented during the ASCO20 Virtual Scientific Program.

Tucatinib combination extends OS in HER2-positive breast cancer with brain metastases
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{ec6da952-b55a-4c7b-bea4-3bd96da58aec}/tucatinib-combination-extends-os-in-her2-positive-breast-cancer-with-brain-metastases

May 29th, 2020 - Tucatinib plus trastuzumab and capecitabine extended OS among patients with brain metastases from HER2-positive breast cancer, according to findings from a randomized phase 3 study presented during the ASCO20 Virtual Scientific Program and simultaneously published in Journal of Clinical Oncology.

Pyrotinib-capecitabine combination improves outcomes in breast cancer subset
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{290284ab-35d9-4048-81cf-662050787639}/pyrotinib-capecitabine-combination-improves-outcomes-in-breast-cancer-subset

May 29th, 2020 - Pyrotinib plus capecitabine extended PFS compared with lapatinib-capecitabine among certain patients with HER2-positive metastatic breast cancer, according to randomized phase 3 study results presented at ASCO20 Virtual Scientific Program.

Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma
https://www.healio.com/hematology-oncology/melanoma-skin-cancer/news/online/{17cd85c5-d78f-4354-9228-85262589c9eb}/adjuvant-pembrolizumab-confers-durable-rfs-benefit-in-resected-stage-iii-melanoma

May 29th, 2020 - Adjuvant pembrolizumab taken for up to 1 year conferred a durable, clinically meaningful RFS benefit for patients with resected high-risk stage III melanoma, according to study results presented during the ASCO20 Virtual Scientific Program.

Anthracycline chemotherapy shows no benefit in HER2-positive breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{fbc5bfee-f64a-43a9-8b6c-b3ea255eca92}/anthracycline-chemotherapy-shows-no-benefit-in-her2-positive-breast-cancer

May 29th, 2020 - Anthracyclines did not improve 3-year efficacy as part of a neoadjuvant chemotherapy regimen for patients with HER2-positive breast cancer, according to results of the TRAIN-2 study presented during the ASCO20 Virtual Scientific Program.

CAR T-cell therapy could ‘revolutionize’ treatment of advanced multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/{808d4883-a0e1-4574-b61d-ec5ce62aa752}/car-t-cell-therapy-could-revolutionize-treatment-of-advanced-multiple-myeloma

May 29th, 2020 - JNJ-4528, a chimeric antigen receptor T-cell therapy, induced early, deep and durable responses among patients with relapsed or refractory multiple myeloma, according to study results presented during the ASCO20 Virtual Scientific Program.

First-line nivolumab plus platinum/etoposide effective in extensive-stage SCLC
https://www.mdedge.com/hematology-oncology/article/223035/lung-cancer/first-line-nivolumab-plus-platinum/etoposide

May 29th, 2020 - While nivolumab plus doublet chemotherapy was effective in extensive-stage small-cell lung cancer (ES-SCLC) in a recent randomized trial, the results might not be sufficient to change current clinical practice, in which two first-line chemo-immunotherapies are already approved and recommended, sources said.

Upfront pembrolizumab doubles PFS in MSI-H/dMMR metastatic colorectal cancer
https://www.mdedge.com/hematology-oncology/article/223031/gastroenterology/upfront-pembrolizumab-doubles-pfs-msi-h/dmmr

May 28th, 2020 - Frontline pembrolizumab doubled progression-free survival (PFS), when compared with chemotherapy, among patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer in the KEYNOTE-177 study.

Adjuvant osimertinib extends DFS in localized NSCLC
https://www.mdedge.com/hematology-oncology/article/222909/lung-cancer/adjuvant-osimertinib-extends-dfs-localized-nsclc

May 27th, 2020 - Adjuvant therapy with osimertinib was associated with a nearly 80% reduction in the risk of disease recurrence or death in patients with stage IB-IIIA non–small cell lung cancer (NSCLC) bearing EGFR mutations, results of the ADAURA trial showed.

Adjuvant osimertinib extends DFS in EGFR-mutated NSCLC
https://www.healio.com/hematology-oncology/lung-cancer/news/online/{641f2259-d903-472a-acbb-681a7bbd3eec}/adjuvant-osimertinib-extends-dfs-in-egfr--mutated-nsclc

May 28th, 2020 - Adjuvant osimertinib significantly prolonged DFS for patients with EGFR-mutated non-small cell lung cancer, according to results of the randomized phase 3 ADAURA trial scheduled for presentation during the ASCO20 Virtual Scientific Program.

Pembrolizumab doubles PFS for certain patients with metastatic colorectal cancer
https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/{4b6f3063-8b62-4e17-ae5f-f28fc400a5ca}/pembrolizumab-doubles-pfs-for-certain-patients-with-metastatic-colorectal-cancer

May 28th, 2020 - First-line pembrolizumab extended PFS vs. chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to findings to be presented during the ASCO20 Virtual Scientific Program.

TRAIN-2: Anthracyclines added toxicity, with no increased efficacy, in HER2+ breast cancer
https://www.mdedge.com/hematology-oncology/article/223040/breast-cancer/train-2-anthracyclines-added-toxicity-no-increased

May 29th, 2020 - Anthracyclines add toxicity with no evidence of improved survival in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy regimen plus dual HER2 blockade, results of a randomized phase 3 trial have suggested.

Moving on up: Maintenance therapy extends OS in bladder cancer
https://www.mdedge.com/hematology-oncology/article/222994/genitourinary-cancer/moving-maintenance-therapy-extends-os

May 27th, 2020 - Is maintenance therapy with an immune checkpoint inhibitor a good idea for patients with advanced bladder cancer who do not progress after initial chemotherapy?

Adjuvant dabrafenib-trametinib provides ‘real chance to cure’ BRAF-mutant melanoma
https://www.healio.com/hematology-oncology/melanoma-skin-cancer/news/online/{9d609f0f-26a9-4518-bcce-059054424e8a}/adjuvant-dabrafenib-trametinib-provides-real-chance-to-cure-braf--mutant-melanoma

May 28th, 2020 - Adjuvant dabrafenib and trametinib provided long-term benefit for patients with resected stage III BRAF V600-mutant melanoma, according to an analysis of the COMBI-AD trial presented during the ASCO20 Virtual Scientific Program.

Pembrolizumab extends PFS in relapsed or refractory classical Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{ca30897b-dbb5-4dcd-a3b6-b01ae581ee67}/pembrolizumab-extends-pfs-in-relapsed-or-refractory-classical-hodgkin-lymphoma

May 28th, 2020 - Pembrolizumab extended PFS compared with brentuximab vedotin for patients with relapsed or refractory classic Hodgkin lymphoma, according to study results presented during the ASCO20 Virtual Scientific Program.

Trastuzumab deruxtecan proves active in HER2-mutated NSCLC
https://www.mdedge.com/hematology-oncology/article/223050/lung-cancer/trastuzumab-deruxtecan-proves-active-her2-mutated

May 30th, 2020 - Among patients with HER2-mutated non–small-cell lung cancer (NSCLC) in an ongoing phase 2 trial, treatment with trastuzumab deruxtecan (T-DXd) has yielded a high response rate, and the median duration of response has not yet been reached, an investigator reported.

Novel LuPSMA Appears More Active in Metastatic Castration-Resistant Prostate Cancer
https://www.targetedonc.com/view/novel-lupsma-appears-more-active-in-metastatic-castration-resistant-prostate-cancer

May 28th, 2020 - Novel agent 177Lu-PSMA-617 (LuPSMA) was more active than cabazitaxel (Jetvana) as treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after docetaxel treatment, according to the findings from the TheraP trial presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

Durable Responses Elicited with Nivolumab Plus Ipilimumab in Advanced NSCLC
https://www.targetedonc.com/view/durable-responses-elicited-with-nivolumab-plus-ipilimumab-in-advanced-nsclc

May 28th, 2020 - Frontline treatment with the combination of with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced durable and long-term efficacy benefits in patients with advanced non-small cell lung cancer (NSCLC) and tumor PD-L1 expression of at least 1% or less than 1%, according to updated results from part 1 of the phase 3 Checkmate 227 trial presented at the 2020 ASCO Virtual Scientific Program.